世界生物精神病学学会联合会(WFSBP)双相障碍生物学治疗指南:2010年双相急性抑郁发作治疗更新
氟西汀*:当奥氮平单药治疗被视为安慰剂设置时(Tohen et al. (2003).)
WFSBP指南于2010年更新,基于循证学利弊对各种药物进行了详尽的分类,上表为证据分类为A和B的治疗手段:被划分为A-1级的药物仅有喹硫平一种,而奥氮平、拉莫三嗪、氟西汀及丙戊酸盐单药治疗,以及奥氮平/氟西汀合剂(OFC)、拉莫三嗪+锂盐、莫达非尼+现有治疗等被划为B-3级。
该指南并未固着于循证学依据的位次排名,提供的是利弊分析及如何治疗双相抑郁的推荐,同时给临床医师预留了充分的自由。WFSBP指南或许是迄今为止这些指南中权衡性最佳、临床最实用的指南。
展开部分内容仅可在
临床指南app 查看下载
收藏
分享
Founded in 1974 in Buenos Aires, Argentina, the World Federation of Societies of Biological Psychiatry is a non-profit, international organization composed of over 60 national societies of biological psychiatry, representing over 4,500 professionals. As a world authority on biological psychiatry, WFSBP is also highly committed to pioneering and promoting the highest levels of education and dissemination within the field.